| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7687075 | SALIX PHARMS | Colonic purgative composition with soluble binding agent |
Jun, 2028
(4 years from now) | |
Osmoprep is owned by Salix Pharms.
Osmoprep contains Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Monobasic, Monohydrate.
Osmoprep has a total of 1 drug patent out of which 0 drug patents have expired.
Osmoprep was authorised for market use on 16 March, 2006.
Osmoprep is available in tablet;oral dosage forms.
The generics of Osmoprep are possible to be released after 22 June, 2028.
Market Authorisation Date: 16 March, 2006
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of OSMOPREP before it's drug patent expiration?
More Information on Dosage
OSMOPREP family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic